Extended Data Fig. 1: Forest plot of subgroup analysis. | Nature Medicine

Extended Data Fig. 1: Forest plot of subgroup analysis.

From: Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

Extended Data Fig. 1

(a) PFS and (b) rPFS in the intention-to-treat (ITT) population. P value and HR are from the unstratified Cox regression model. Prior local therapy included prior radical prostatectomy or radiotherapy. PD-L1–positive immune cells (IC) defined as: IC0, <1%; IC1/2/3, ≥1%; IC2/3, ≥5%.

Back to article page